David J. Matlin - 13 Jan 2026 Form 4 Insider Report for Clene Inc. (CLNN)

Reporting relationship: Director
Issuer ticker: CLNN
Reported as of: 13 Jan 2026
Net transaction value: +$216,664
SEC form: 4
Accepted by SEC: 13 Jan 2026, 14:48:54 UTC
Prior SEC filing: 14 Nov 2025
Next SEC filing: 20 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Jerome T. Miraglia POA

Key filing fact

David J. Matlin filed Form 4 for Clene Inc. (CLNN) on 13 Jan 2026.

Key facts

This page summarizes David J. Matlin's Form 4 filing for Clene Inc. (CLNN).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 13 Jan 2026, 14:48.

Change

Previous filing in this sequence was filed on 14 Nov 2025.
Current net transaction value: +$216,664.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001251956 Primary reporting owner

MATLIN DAVID J

Relationship: Director
Address: 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Signature: /s/ Jerome T. Miraglia POA
Signature date: 13 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLNN transaction

common stock

Purchase

Transaction value: $216,664
Shares: +33,333
Change %: +7.5%
Price: $6.50
Shares after: 477,824
Date: 13 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLNN transaction Derivative

Warrant (right to buy)

Award

Transaction value
Shares: +40,000
Change %
Price
Shares after: 40,000
Date: 13 Jan 2026
Ownership: Direct
Underlying class: common stock
Underlying amount
Exercise price: $6.00
Footnotes: F2, F3, F4

CLNN transaction Derivative

Warrant (right to buy)

Award

Transaction value
Shares: +93,333
Change %
Price
Shares after: 93,333
Date: 13 Jan 2026
Ownership: Direct
Underlying class: common stock
Underlying amount
Exercise price: $6.00
Footnotes: F2, F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The reporting person entered into a Securities Purchase Agreement with Clene Inc. and the other parties thereto, dated January 8, 2026, for the purchase of 33,333 shares of the Company's common stock, Series A Warrants to purchase 40,000 shares of the Company's common stock and Series B Warrants to purchase 93,333 shares of the Company's common stock, closing effective January 13, 2026.

Footnote F2

The price of each Unit is $6.50 consisting of one share of Common Stock of Clene, one Series A Warrant and one Series B Warrant.

Footnote F3

The exercise price of each Series A Warrant will increase from $6.00 to $7.00 per share if either: (a) the warrant is exercised prior to the Company's public announcement of the U.S. Food and Drug Administration's (the "FDA") posted action date under the Prescription Drug User Fee Act for the Company's new drug application ("NDA") for CNM-Au8 (the "Series A Trigger Announcement "); or (b) the volume-weighted average price (the "VWAP") of the Company's common stock equals or exceeds $10.00 on the measurement date associated with the Series A Trigger Announcement.

Footnote F4

The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $6,684,000 by the applicable exercise price.

Footnote F5

The exercise price for each Series B Warrant will increase from $6.00 to $12.50 per share if: (i) the Series B Warrant is exercised prior to the Company's public announcement of its receipt of written approval from the FDA of its NDA for CNM-Au8 in ALS or (ii) the VWAP of the Company's common stock is equal to or greater than $25.00 on the associated measurement date. The exercise price of the Series B Warrant will increase to $10.00 per share if the VWAP of the Company's common stock is equal to or greater than $20.00 on the associated measurement date.

Footnote F6

The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $15,596,000 by the applicable exercise price.